CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04684641|
Recruitment Status : Active, not recruiting
First Posted : December 24, 2020
Results First Posted : March 3, 2023
Last Update Posted : March 3, 2023
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
This is a Phase 2 study with primary objective of looking whether YPT-01 phage therapy reduces sputum bacterial load in cystic fibrosis subjects with Pseudomonas aeruginosa.
In addition, study evaluates the safety profile of phage therapy in this patient population.
|Condition or disease||Intervention/treatment||Phase|
|Cystic Fibrosis||Drug: Standard Dose YPT-01 Other: Placebo||Phase 1 Phase 2|
This is a prospective, randomized, placebo-controlled, double-blinded, single-site study of Yale Phage Therapy (YPT) 01 in cystic fibrosis subjects with chronic Pseudomonas aeruginosa airway infections. The study has 2 parallel arms of phage therapy and placebo, with all study materials GMP-manufactured. The purpose of this study is to demonstrate efficacy and safety of inhaled (nebulized) phage therapy YPT-01. Clinically stable subjects who have confirmed diagnosis of CF with PsA in sputum cultures on at least two occasions within past year, and in sputum at screening visit, will be recruited into this study.
An open-label extension is available for subjects in the placebo group to receive YPT-01 following completion of blinded portion of the study.
Nov 2022 study ended enrollment after 8 subjects. The Double-Blind Randomized portion of the study was closed and the Open-Label Extension was opened.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||8 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||CYstic Fibrosis bacterioPHage Study at Yale (CYPHY): A Single-site, Randomized, Double-blind, Placebo-controlled Study of Bacteriophage Therapy YPT-01 for Pseudomonas Aeruginosa Infections in Adults With Cystic Fibrosis|
|Actual Study Start Date :||March 29, 2021|
|Actual Primary Completion Date :||September 1, 2022|
|Estimated Study Completion Date :||March 2023|
Experimental: Phage therapy
Participants will be randomized to receive 3mL phage therapy, nebulized daily for 7 days.
Drug: Standard Dose YPT-01
Participants will be randomized to receive the standard dose of phage therapy YPT-01.
Other Name: Phage Therapy
Active Comparator: Placebo
Participants will be randomized to receive the 3mL placebo, nebulized daily for 7 days.
Participants will be randomized to receive the placebo.
- Reduction in Sputum Bacterial Culture [ Time Frame: Day 14 ]Reduction in sputum bacterial culture titers of Pseudomonas as measured by colony forming units/mL at day 14
- Change in Lung Function [ Time Frame: Screening, day 14, day 21, day 28, and day 56 ]Change in lung function [percent predicted forced expiratory volume in 1 second (FEV1pp)] in subjects randomized to phage therapy and placebo from screening to day 14, 21, 28, and 56
- Change in the Rate of Pulmonary Exacerbations [ Time Frame: Baseline, day 56 ]Compare the rates of pulmonary exacerbations between subjects randomized to phage therapy versus placebo during the first 56 days of the study
- Change in the Rate of Hospitalization [ Time Frame: Baseline, day 56 ]Compare the rates of hospitalizations between subjects randomized to phage therapy versus placebo during the first 56 days of the study
- Change in the Rate of Acute Antibiotic Use [ Time Frame: Baseline, day 56 ]Compare the rates of acute antibiotic use between subjects randomized to phage therapy versus placebo during the first 56 days of the study
- Patient's Quality of Life [ Time Frame: Baseline, day 56 ]Compare the changes in subject-reported quality of life, using the CFQR, between subjects randomized to phage therapy versus placebo during the first 56 days of the study. This survey consists of 50 questions that relate to a subjects clinical condition and mental health. Administration time takes 10 minutes
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Capable of giving signed informed consent;
- Stated willingness to comply with all study procedures and availability for the duration of the study;
- Age ≥18;
- CF diagnosis based upon genetics, sweat chloride testing, or clinical manifestations;
- Able to provide repeated induced sputum samples;
- Able to use a nebulizer;
- PsA culture positive on one occasions within past 2 years and in sputum at screening visit;
- FEV1 >40%;
- Clinically stable lung disease, defined as no decrease in FEV1 >10% or pulmonary exacerbations in the 4 weeks prior to screening;
- If on CF modulator therapy (e.g., ivacaftor, ivacaftor/elexacaftor/tezacaftor), then subject remains on the same modulator therapy for at least 2 months prior to enrollment;
- For females of reproductive potential: use of effective contraception for at least 1 month prior to screening and agreement to use 2 methods of effective contraception during study participation and for an additional 6 weeks after the end of YPT-01 administration;
- Males of non-reproductive potential (e.g., documented congenital bilateral absence of vas deferens) or males of reproductive potential (e.g., non-vasectomized males or males vasectomized less than 120 days prior to study start) that agree to use condoms with spermicide while engaging in sexual activity or be sexually abstinent.
- History of solid organ transplant (e.g., lung or liver);
- Severe neutropenia, as defined by absolute neutrophil count (ANC) of < 500 per microliter;
- No YPT-01 phage identified that effectively targets sputum PsA;
- Treatment for pulmonary exacerbation within the prior 4 weeks;
- Change in pulmonary medications within the prior 4 weeks;
- Subjects who are pregnant, who intend to become pregnant, or who do not wish to use contraception;
- Subjects who are breastfeeding;
- Participation in another clinical research study concurrently or within the prior 2 months;
- Known allergy to soy, egg, yeast, or meat.
- Any genetic or acquired (including medication-induced) immunocompromised condition, beyond the level of immunocompromise typically associated with CF and its management.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04684641
|United States, Connecticut|
|Yale New Haven Hospital|
|New Haven, Connecticut, United States, 06520|
|Study Director:||Jonathan Koff, MD||Yale University|
|Principal Investigator:||Benjamin Chan, PhD||Yale University|
Documents provided by Jonathan Koff, Yale University:
|Responsible Party:||Jonathan Koff, Director, Adult Cystic Fibrosis Program, Yale University|
|Other Study ID Numbers:||
20-004179 ( Other Grant/Funding Number: Cystic Fibrosis Foundation (CFF) )
|First Posted:||December 24, 2020 Key Record Dates|
|Results First Posted:||March 3, 2023|
|Last Update Posted:||March 3, 2023|
|Last Verified:||February 2023|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Digestive System Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases